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Breast cancer exhibits familial aggregation, consistent with variation in genetic susceptibility to the disease. Known
susceptibility genes account for less than 25% of the familial risk of breast cancer, and the residual genetic variance is likely
to be due to variants conferring more moderate risks. To identify further susceptibility alleles, we conducted a two-stage
genome-wide association study in 4,398 breast cancer cases and 4,316 controls, followed by a third stage in which 30 single
nucleotide polymorphisms (SNPs) were tested for confirmation in 21,860 cases and 22,578 controls from 22 studies. We
used 227,876 SNPs that were estimated to correlate with 77% of known common SNPs in Europeans at r2.0.5. SNPs in five
novel independent loci exhibited strong and consistent evidence of association with breast cancer (P, 1027). Four of these
contain plausible causative genes (FGFR2,TNRC9,MAP3K1 and LSP1). At the second stage, 1,792 SNPswere significant at the
P,0.05 level comparedwith an estimated 1,343 that would be expected by chance, indicating thatmany additional common
susceptibility alleles may be identifiable by this approach.
Breast cancer is about twice as common in the first-degree relatives of
women with the disease as in the general population, consistent with
variation in genetic susceptibility to the disease1. In the 1990s, two
major susceptibility genes for breast cancer,BRCA1 andBRCA2, were
identified2,3. Inherited mutations in these genes lead to a high risk of
breast and other cancers4. However, the majority of multiple case
breast cancer families do not segregate mutations in these genes.
Subsequent genetic linkage studies have failed to identify further
major breast cancer genes5. These observations have led to the pro-
posal that breast cancer susceptibility is largely ‘polygenic’: that is,
susceptibility is conferred by a large number of loci, each with a small
effect on breast cancer risk6. This model is consistent with the ob-
served patterns of familial aggregation of breast cancer7. However,
progress in identifying the relevant loci has been slow. As linkage
studies lack power to detect alleles withmoderate effects on risk, large
case-control association studies are required. Such studies have iden-
tified variants in the DNA repair genes CHEK2, ATM, BRIP1 and
PALB2 that confer an approximately twofold risk of breast cancer,
but these variants are rare in the population8–14. A recent study has
shown that a common coding variant in CASP8 is associated with a
moderate reduction in breast cancer risk15. After accounting for all
the known breast cancer loci, more than 75% of the familial risk of
the disease remains unexplained16.
Recent technological advances have provided platforms that allow
hundreds of thousands of SNPs to be analysed in association studies,
thus providing a basis for identifying moderate risk alleles without
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prior knowledge of position or function. It has been estimated that
there are 7million common SNPs in the human genome (withminor
allele frequency, m.a.f., .5%)17. However, because recombination
tends to occur at distinct ‘hot-spots’, neighbouring polymorphisms
are often strongly correlated (in ‘linkage disequilibrium’, LD) with
each other. Themajority of common genetic variants can therefore be
evaluated for association using a few hundred thousand SNPs as tags
for all the other variants18. We aimed to identify further breast cancer
susceptibility loci in a three-stage association study19. In the first
stage, we used a panel of 266,722 SNPs, selected to tag known com-
mon variants across the entire genome18. These SNPs were genotyped
in 408 breast cancer cases and 400 controls from the UK; data were
analysed for 390 cases and 364 controls genotyped for $80% of
the SNPs. The cases were selected to have a strong family history of
breast cancer, equivalent to at least two affected female first-degree
relatives, because such cases are more likely to carry susceptibility
alleles20. Initally, we analysed 227,876 SNPs (85%) with genotypes on
at least 80% of the subjects. We estimate that these SNPs are corre-
lated with 58% of common SNPs in the HapMap CEPH/CEU (Utah
residents with ancestry from northern and western Europe) samples
at r2. 0.8, and 77% at r2. 0.5 (mean r25 0.75; see Supplementary
Fig. 1) (http://www.hapmap.org/)21. As expected, coverage was
strongly related tom.a.f.: 70%of SNPswithm.a.f.. 10%were tagged
at r2. 0.8, comparedwith 23%of SNPswithm.a.f. 5–10%. Themain
analyses were restricted to 205,586 SNPs that had a call rate of 90%
and whose genotype distributions did not differ from Hardy–
Weinberg equilibrium in controls (at P, 1025).
For the second stagewe selected 12,711 SNPs, approximately 5%of
those typed in stage 1, on the basis of the significance of the difference
in genotype frequency between cases and controls. These SNPs were
then genotyped in a further 3,990 invasive breast cancer cases and
3,916 controls from the SEARCH study, using a custom-designed
oligonucleotide array. In the main analyses, we considered 10,405
SNPs with call rate of .95% that did not deviate from Hardy–
Weinberg equilibrium in controls.
Comparison of the observed and expected distribution of test stat-
istics showed some evidence for an inflationof the test statistics inboth
stage 1 (inflation factor l5 1.03, 95% confidence interval (CI) 1.02–
1.04) and stage 2 (l5 1.06, 95%CI 1.04–1.12), based on the 90% least
significant SNPs (Fig. 1). Possible explanations for this inflation
include population stratification, cryptic relatedness among subjects,
and differential genotype calling between cases and controls. There
was evidence for an excess of low call rate SNPs among the most
significant SNPs (P, 0.01) in stage 1, but not in stage 2, suggesting
that some of this effect is a genotyping artefact (Supplementary Table
1). However, the inflation was still present among SNPs with call rate
.99% in both cases and controls, possibly reflecting population sub-
structure.We computed 1degree of freedom(d.f.) association tests for
each SNP, combining stages 1 and2.After adjustment for this inflation
by the genomic controlmethod22, we observedmore associations than
would have been expected by chance at P, 0.05 (Table 1). One SNP
(dbSNP rs2981582) was significant at the P, 1027 level that has been
proposed as appropriate for genome-wide studies23.
In the third stage, to establish whether any SNPs were definitely
associated with risk, we tested 30 of the most significant SNPs in 22
additional case-control studies, comprising 21,860 cases of invasive
breast cancer, 988 cases of carcinoma in situ (CIS) and 22,578 controls
(Supplementary Table 2). Six SNPs showed associations in stage 3 that
were significant at P# 1025 with effects in the same direction as in
stages 1 and 2 (Table 2, Supplementary Table 3, and Fig. 2). All these
SNPs reached a combined significance level ofP, 1027 (ranging from
23 10276 to 33 1029). Of these six SNPs, five were within genes or
LD blocks containing genes. SNP rs2981582 lies in intron 2 of FGFR2
(also known as CEK3), which encodes the fibroblast growth factor
receptor 2. SNPs rs12443621 and rs8051542 are both located in an
LD block containing the 59 end of TNRC9 (also known as TOX3), a
gene of uncertain function containing a tri-nucleotide repeatmotif, as
well as the hypothetical gene, LOC643714. SNP rs889312 lies in an LD
block of approximately 280 kb that containsMAP3K1 (also known as
MEKK), which encodes the signalling protein mitogen-activated pro-
tein kinase kinase kinase 1, in addition to two other genes:MGC33648
andMIER3. SNP rs3817198 lies in intron 10 of LSP1 (also known as
WP43), encoding lymphocyte-specific protein 1, an F-actin bundling
cytoskeletal protein expressed in haematopoietic and endothelial cells.
A further SNP, rs2107425, located just 110 kilobases (kb) from
rs3817198, was also identified (overall P5 0.00002). rs2107425 is
within theH19 gene, an imprinted maternally expressed untranslated
messenger RNA closely involved in regulation of the insulin growth
factor gene, IGF2. In stage 3, however, rs2107425 was only weakly
significant after adjustment for rs3817198 by logistic regression
(P5 0.06). This suggests that the association with breast cancer risk
may be driven by variants in LSP1 rather than inH19. The sixth SNP
reaching a combined P, 1027 was rs13281615, which lies on 8q. It is
correlated with SNPs in a 110 kb LD block that contains no known
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Figure 1 | Quantile–quantile plots for the test statistics (Cochran-
Armitage 1 d.f. x2 trend tests) for stages 1 and 2. a, Stage 1; b, stage 2. Black
dots are the uncorrected test statistics. Red dots are the statistics corrected by
the genomic control method (l5 1.03 for stage 1, l5 1.06 for stage 2).
Under the null hypothesis of no association at any locus, the points would be
expected to follow the black line.
Table 1 | Number of significant associations after stage 2
Level of significance Observed Observed
adjusted*
Expected Ratio
0.01–0.05 1,239 1,162 934.3 1.24
0.001–0.01 574 517 347.6 1.49
0.0001–0.001 112 88 53.3 1.65
0.00001–0.0001 16 12 7.0 1.71
,0.00001 15 13 0.96 13.5
All P, 0.05 1,956 1,792 1,343.2 1.33
Observed numbers of SNPs associated with breast cancer after stage 2, by level of significance,
before and after adjustment for population stratification, and expected numbers under the null
hypothesis of no association.
* Adjusted for inflation of the test statistic by the genomic control method.
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genes. The basis of this association therefore remains obscure. This
SNP is approximately 130 kb proximal to rs1447295, 60 kb proximal
to rs6983267 and 230 kb distal to rs16901979, recently shown to be
associated with prostate cancer24–26.
In addition to the seven SNPs described above, there was evidence
of association among the remaining 23 SNPs (global P5 0.001 in
stage 3). In particular, three SNPs showed some evidence of asso-
ciation in stage 3 (P, 0.05, in each case in the same direction as in
stages 1 and 2; Table 2). SNPs rs981782 and rs30099 both lie in the
centromeric region of chromosome 5. rs4666451 lies on 2p, a region
for which some evidence of linkage to breast cancer in families has
been reported5. The 20 other SNPs showed no evidence of association
in stage 3 (global P5 0.11), suggesting thatmost of these associations
from stages 1 and 2 were false positives.
FGFR2
Themost significantly associated SNP, rs2981582, lieswithin a 25 kbLD
block almost entirely within intron 2 of FGFR2. We found no evidence
of associationwith SNPs elsewhere in the gene (Fig. 3a). In an attempt to
identify a causal variant, we first identified the 19 common variants
(m.a.f.. 0.05) in this block fromHapMapCEUdata.Thesewere tagged
(r2. 0.8) by 7 SNPs including rs2981582. The additional tag SNPswere
genotyped in the SEARCH study cases and controls. Multiple logistic
regression analysis of these variants found no additional evidence for
association after adjusting for rs2981582. Haplotype analysis of these 7
SNPs indicated thatmultiple haplotypes carrying theminor (a) allele of
rs2981582were associatedwith an increased riskof breast cancer, imply-
ing that the association was being driven by rs2981582 itself or a variant
strongly correlated with it (Supplementary Table 4).
Table 2 | Summary of results for eleven SNPs selected for stage 3 that showed evidence of an association with breast cancer
rs Number Gene Position* m.a.f.{ Per allele OR
(95% CI)
HetOR
(95% CI)
HomOR
(95% CI)
P-trend
Stages
1 and 2
Stage3 Combined
rs2981582 FGFR2 10q
123342307
0.38
(0.30)
1.26
(1.23–1.30)
1.23
(1.18–1.28)
1.63
(1.53–1.72)
43 10216 53 10262 23 10276
rs12443621 TNRC9/
LOC643714
16q
51105538
0.46
(0.60)
1.11
(1.08–1.14)
1.14
(1.09–1.20)
1.23
(1.17–1.30)
1027 93 10214 23 10219
rs8051542 TNRC9/
LOC643714
16q
51091668
0.44
(0.20)
1.09
(1.06–1.13)
1.10
(1.05–1.16)
1.19
(1.12–1.27)
43 1026 43 1028 10212
rs889312 MAP3K1 5q
56067641
0.28
(0.54)
1.13
(1.10–1.16)
1.13
(1.09–1.18)
1.27
(1.19–1.36)
43 1026 33 10215 73 10220
rs3817198 LSP1 11p
1865582
0.30
(0.14)
1.07
(1.04–1.11)
1.06
(1.02–1.11)
1.17
(1.08–1.25)
83 1026 1025 33 1029
rs2107425 H19 11p
1977651
0.31
(0.44)
0.96
(0.93–0.99)
0.94
(0.90–0.98)
0.95
(0.89–1.01)
73 1026 0.01 23 1025
rs13281615 8q
128424800
0.40
(0.56)
1.08
(1.05–1.11)
1.06
(1.01–1.11)
1.18
(1.10–1.25)
23 1027 63 1027 53 10212
rs981782 5p
45321475
0.47
(0.37)
0.96
(0.93–0.99)
0.96
(0.92–1.01)
0.92
(0.87–0.97)
83 1025 0.003 93 1026
rs30099 5q
52454339
0.08
(0.39)
1.05
(1.01–1.10)
1.06
(1.00–1.11)
1.09
(0.96–1.24)
0.003 0.02 0.001
rs4666451 2p
19150424
0.41
(0.04)
0.97
(0.94–1.00)
0.98
(0.93–1.02)
0.93
(0.87–0.99)
53 1026 0.04 63 1025
rs3803662{ TNRC9/
LOC643714
16q
51143842
0.25
(0.60)
1.20
(1.16–1.24)
1.23
(1.18–1.29)
1.39
(1.26–1.45)
33 10212 10226 10236
OR, odds ratio; HetOR, odds ratio in heterozygotes; HomOR, odds ratio in rare homozygotes (relative to common homozygotes); CI, confidence interval.
* Build 36.2 position.
{Minor allele frequency in SEARCH (UK) study. Combined allele frequency from three Asian studies in italics.
{ rs3803662 was not part of the initial tag SNP set but identified as a result of fine-scale mapping of the TNRC9/LOC643714 locus and typed in the stage 2 and stage 3 sets (but not the stage 1 set).
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Figure 2 | Forest plots of the per-allele odds ratios for each of the five SNPs
reachinggenome-widesignificance. a, rs2981582;b, rs3803662; c, rs889312;
d, rs13281615; and e, rs3817198. The x-axis gives the per-allele odds ratio.
Each row represents one study (see Supplementary Table 2), with summary
odds ratios for all European and all Asian studies, and all studies combined.
The area of the square for each study is proportional to the inverse of the
variance of the estimate. Horizontal lines represent 95% confidence
intervals. Diamonds represent the summary odds ratios, with 95%
confidence intervals, based on the stage 3 studies only.
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Resequencing of this region in 45 subjects of European origin
identified 29 variants that were strongly correlated with rs2981582
(r2. 0.6) (http://cgwb.nci.nih.gov; Fig. 3b and Supplementary
Tables 5–8). A subset of 14 variants tagged 27 of these in European
(r2. 0.95) and Asian (Korean) samples (r2. 0.86). Two variants
could not be genotyped reliably. This new tagging set was then gen-
otyped in SEARCH and 3 studies from Asian populations; the Asian
studies were included because the LD is weaker, providing greater
power to resolve the causal variant (Fig. 3b, left panel). The strongest
association was found with rs7895676. On the assumption that there
is a single disease-causing allele, we calculated a likelihood for each
variant. 21 SNPs (including rs2981582) had a likelihood ratio of,1/
100 relative to rs7895676, indicating that none of these are likely to be
the causal variant (Supplementary Table 8). Six variants were too
strongly correlated for their individual effects to be separated using
a genetic epidemiological approach. Functional assays will be
required to determine which is causally related to breast cancer risk.
Intron 2 of FGFR2 shows a high degree of conservation in mam-
mals, and contains several putative transcription-factor binding sites
(http://genomequebec.mcgill.ca/PReMod)27, some of which lie in
close proximity to the relevant SNPs. We therefore speculate that
the association with breast cancer risk ismediated through regulation
of FGFR2 expression. Of possible relevance is that only three of these
variants (rs10736303, rs2981578 and rs35054928) are within
sequences conserved across all placental mammals (Fig. 3c and
Supplementary Table 8). Of these, the disease associated allele of
rs10736303 generates a putative oestrogen receptor (ER) binding site.
rs35054928 lies immediately adjacent to a perfect POU domain pro-
tein octamer (Oct) binding site. However, multiple splice variants
have been reported in FGFR2, and differential splicingmight provide
an alternative mechanism for the association. FGFR2 is a receptor
tyrosine kinase that is amplified and overexpressed in 5–10% of
breast tumours28–30. Somatic missense mutations of FGFR2 that are
likely to be implicated in cancer development have also been demon-
strated in primary tumours and cell lines of multiple tumour types
(http://www.sanger.ac.uk/genetics/CGP/cosmic/)30,31.
TNRC9/LOC643714 locus
As two SNPs in the TNRC9/LOC643714 locus, rs12443621 and
rs8051542, both showed convincing evidence of association,we further
evaluated this region by genotyping, in the SEARCH set, an additional
19 SNPs tagging 101 common variants within the entire TNRC9 and
LOC643714 genes, based on the HapMap CEU data. SNPs tagging the
coding regionofTNRC9 showednoevidenceof association.The stron-
gest association was observed with rs3803662, a synonymous coding
SNP of LOC643714 that lies 8 kb upstream of TNRC9. This SNP was
therefore genotyped in the stage 3 set (Table 2). Logistic regression
analysis indicated that rs3803662 exhibited a stronger association with
disease than other SNPs, and the associations with other SNPs were
non-significant after adjustment for rs3803662. These results suggest
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Figure 3 | The FGFR2 locus. a, Map of the whole
FGFR2 gene, viewed relative to common SNPs on
HapMap. The gene is 126 kb long and in reverse
39–59 orientation on chromosome 10. Exon
positions are illustrated with respect to the 67
SNPs with m.a.f.. 5% in HapMap CEU
(therefore the map is not to physical scale).
Numbered SNPs are those tested in the genome-
wide study. SNPs in black were not significant in
stage 1. Those in red were significant at
P, 0.0001 after stage 2. rs10510097 (orange) was
significant in stage 1, but failed quality control in
stage 2 owing to deviation fromHardy–Weinberg
equilibrium. Squares indicate pairwise r2 on a
greyscale (black5 1, white5 0). Red circle
indicates rs2981582. b, Resequenced 32 kb
region, shown relative to SNPs in CEU with
m.a.f.. 5%, showing pairwise LD for SNPs in
HapMap CEU (left panel) and JPT/CHB (right
panel). Red circle indicates rs2981582, shown in
bold black. c, Sequence conservation of 32 kb
region in five species, relative to human sequence
(http://pipeline.lbl.gov/methods.shtml)35. Red
circle indicates rs2981582. SNPs in grey are those
used in the initial tagging of known common
HapMap SNPs within the block. SNPs in black
are correlated with rs2981582 with r2. 0.6 in
European samples. Six SNPs in red were those
consistent with being the causative variant on the
basis of the genetic data (not excluded at odds of
100:1 relative to the SNP with the strongest
association, rs7895676).
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that the causal variant is closely correlated with rs3803662. Four SNPs
in the HapMap CEU data (rs17271951, rs1362548, rs3095604 and
rs4784227) that span LOC643714 and the 59 regulatory regions of
TNRC9 are strongly correlated with rs3803662, and it therefore
remains unclear in which gene the causative variant lies. TNRC9 con-
tains a putativeHMG(highmobility group) boxmotif, suggesting that
it might act as a transcription factor.
Pattern of risks
We assessed in more detail, in the stage 3 data, the pattern of the
risks associated with the five independent SNPs that reached an over-
all P, 1027: rs2981582 (FGFR2), rs3803662 (TNRC9/LOC643714),
rs889312 (MAP3K1), rs13281615 (8q) and rs3817198 (LSP1). For each
of these five SNPs, theminor allele in Europeans was associated with an
increased risk of breast cancer in a dose-dependent manner, with a
higher risk of breast cancer in homozygous than in heterozygous car-
riers. Simple dominant and recessive models could be rejected for each
SNP (all P5 0.02 or less). There was a marked difference in allele
frequencies between populations, with the risk-associated alleles of
rs8051542, rs889312 and rs13281615 being the major allele in Asian
populations. The per allele odds ratio associated with rs2981582 was
significantly smaller, though still elevated, in the Asian versus European
populations (P5 0.04 for difference in odds ratio). This difference is
consistent with the hypothesis that rs2981582 is not the functional
variant at the FGFR2 locus, andwas not seen for SNPs exhibiting stron-
ger evidence in the fine-scale mapping. No other evidence for hetero-
geneity in the per-allele odds ratio among studies was observed (Fig. 2).
Three of the SNPs (rs2981582, rs3803662 and rs889312) also
showed evidence of association with breast CIS (Supplementary
Table 9). For rs2981582 and rs3803662, the estimated odds ratios were
greater for a diagnosis of breast cancer before age 40 years, but the
trends by age were not statistically significant (Supplementary Table
10). There was evidence of an association with family history of breast
cancer for three SNPs: for rs2981582 (P5 0.02), rs3803662 (P5 0.03)
and rs13281615 (P5 0.05), the susceptibility allele was commoner in
women with a first-degree relative with the disease than in those
without (Supplementary Table 11). rs2981582 was also associated
with bilaterality (P5 0.02). The associations with family history and
bilaterality are to be expected for susceptibility loci, and are similar to
previous observations for alleles inCHEK2 and ATM (refs 10, 12, 14).
Discussion
This study has identified five novel breast cancer susceptibility loci,
and demonstrated conclusively that some of the variation in breast
cancer risk is due to common alleles. None of the loci we identified
had been previously reported in association studies. Most previously
identified breast cancer susceptibility genes are involved in DNA
repair, and many association studies in breast cancer have concen-
trated on genes in DNA repair and sex hormone synthesis and meta-
bolism pathways. None of the associations reported here appear to
relate to genes in these pathways. It is notable that three of the five loci
contain genes related to control of cell growth or to cell signalling, but
only one (FGFR2) had a clear prior relevance to breast cancer. These
results should, therefore, open up new avenues for basic research.
Our results emphasize the critical importance of study size in gen-
etic association studies. It is notable that none of the confirmed asso-
ciations reached genome-wide significance after stage 1 and only one
reached this level after stage 2. As most common cancers have similar
familial relative risks to breast cancer, it is likely that similarly large
studies will be required to identify common alleles for other cancers.
The fine-scale mapping of the FGFR2 locus demonstrates that, even
with a clear association, identification of the causative variant can be
extremely problematic. However, the use of studies from multiple
populations with different patterns of LD can substantially reduce
the number of variants that need to be subjected to functional analysis.
As these susceptibility alleles are very common, a highproportion of
the general population are carriers of at-risk genotypes. For example,
approximately 14% of the UK population and 19% of UK breast
cancer cases are homozygous for the rare allele at rs2981582. On the
other hand, the increased risks associated with these alleles are rela-
tively small—on the basis ofUKpopulation rates, the estimated breast
cancer risk by age 70 years for rare homozygotes at rs2981582 is 10.5%,
compared to 6.7% in heterozygotes and 5.5% in common homozy-
gotes. At this stage, it is unlikely that these SNPswill be appropriate for
predictive genetic testing, either alone or in combination with each
other. However, as further susceptibility alleles are identified, a com-
bination of such alleles together with other breast cancer risk factors
may become sufficiently predictive to be important clinically.
On the basis of the relative risk estimates from stage 3, and assuming
that the five most significant loci interact multiplicatively on disease
risk, these loci explain an estimated 3.6% of the excess familial risk of
breast cancer. On the basis of our staged design and the estimated
distribution of linkage disequilibrium between the typed SNPs and
those in HapMap, we estimate that the power to identify the five most
significant associations at P, 1027 (rs2981582, rs3803662, rs889312,
rs13281615 and rs3817198) was 93%, 71%, 25%, 3% and 1% respect-
ively. These estimates are uncertain, notably because the true coverage
ofHapMapSNPs is unknown.Nevertheless, these calculations indicate
that the power to detect the two strongest associations was high, and
suggest that there are likely to be few other common variants with a
similar effect on variation in breast cancer risk to rs2981582. In con-
trast, the low power to detect rs13281615 and rs3817198 suggests that
these variantsmay represent amuch larger class of loci, each explaining
of the order of 0.1% of the familial risk of breast cancer. An example of
such a locus is provided by CASP8 D302H, which showed strong
evidence of association in a previous large study15. This SNPwas tested
in stage 1, but the association was missed because it did not reach the
threshold for testing in stage 2. The excess of associations after stage 2 is
also consistent with the existence of many such loci. In addition,
because the coverage for SNPs with m.a.f., 10% was low, many low
frequency alleles may have been missed. The detection of further sus-
ceptibility loci will require genome-wide studies with more complete
coverage and using larger numbers of cases and controls, together with
the combination of results across multiple studies. The present study
demonstrates that common susceptibility loci can be reliably iden-
tified, and that they may together explain an appreciable fraction of
the genetic variance in breast cancer risk.
METHODS SUMMARY
Cases for stage 1 were identified through clinical genetics centres in the UK and a
national study of bilateral breast cancer. Cases in stage 2 were drawn from a
population-based study of breast cancer (SEARCH)32. Controls for stages 2 and 3
were drawn from EPIC-Norfolk, a population-based study of diet and cancer33.
Cases and controls for stage 3 were identified through case-control studies in
Europe, North America, South-East Asia and Australia participating in the
Breast Cancer Association Consortium (Supplementary Table 2)34.
Genotyping for stages 1 and 2 was conducted using high-density oligonucleo-
tidemicroarrays. For the main analyses, we excluded samples called on#80% of
SNPs in either stage. We also excluded SNPs that achieved a call rate of#90% in
stage 1 and#95% in stage 2, and SNPs whose frequency deviated from Hardy–
Weinberg equilibrium in controls atP, 0.00001.Genotyping for stage 3, and for
the fine-scale mapping of the FGFR2 locus, was conducted using either a 59
nuclease assay (Taqman, Applied Biosystems) or MALDI-TOF mass spectro-
metry using the Sequenom iPLEX system. For each centre, we excluded any
sample called on #80% of SNPs, and any SNP with a call rate of #95% or a
deviation from Hardy–Weinberg equilibrium in controls at P, 0.00001. Tests
of association were 1 d.f. Cochran-Armitage tests, stratified for stage, centre and
ethnic group (European or Asian). Odds ratios for each SNP were estimated
using stratified logistic regression, using the stage 3 data only.
Full Methods and any associated references are available in the online version of
the paper at www.nature.com/nature.
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METHODS
Subjects. Cases in stage 1 were identified through clinical genetics centres in
Cambridge (n5 91), Manchester (96) and Southampton (136), and a national
study of bilateral breast cancer (85). Cases were women diagnosed with invasive
breast cancer under the age of 60 years whohad a family history score of at least 2,
where the score was computed as the total number of first-degree relatives plus
half the number of second-degree relatives affected with breast cancer. The score
for women with bilateral breast cancer was increased by 1, so that women were
eligible if they were diagnosed with bilateral breast cancer and had one affected
first-degree relative. Cases known to carry a BRCA1 or BRCA2 mutation were
excluded. Controls were selected from the EPIC-Norfolk study, a population-
based cohort study of diet and cancer based in Norfolk, East Anglia, UK33.
Controls were chosen to be women aged over 50 years and free of cancer at
the time of entry. Genotyping was attempted on 408 cases, plus 32 duplicate
case samples, and 400 controls. For the analysis in Table 1, 54 samples with
genotype call rates ,80% were excluded, so the final analyses were based on
390 cases and 364 controls. The minimum genotype call rate for the remaining
samples was 89%. The overall genotype discordance rate between duplicate
samples in stage 1 was 0.01%.
For stage 2, invasive breast cancer cases were drawn from SEARCH, a popu-
lation-based study of cancer in East Anglia32. Controls were women selected
from the EPIC-Norfolk study, as previously described33. Eighty-eight subjects
whowere also genotyped in stage 1, and 35 controls who subsequently developed
breast cancer and were also in the case series, were excluded from the analysis,
leaving 3,990 breast cancer cases and 3,916 controls, plus five duplicates. The
overall rate of discordance of genotypes between duplicate samples in stage 2 was
0.008%.
Twenty-one additional studies were included in stage 3 (see Supplementary
Table 2). These studies participated through the Breast Cancer Association
Consortium, an ongoing collaboration among investigators conducting case-
control association studies in breast cancer15,33. All studies provided information
on disease status (invasive breast cancer, carcinoma in situ or control), age at
diagnosis/observation, ethnic group, first-degree family history of breast cancer
and bilaterality of breast cancer. One further study (Breast Cancer Study of
Taiwan) was included in the fine-scale mapping of the FGFR2 locus.
Genotyping. For stage 1, genotyping was performed on 200 ng DNA that was
first subjected to whole genome amplification using Multiple Displacement
Amplification (MDA)36. Samples were then genotyped for a set of 266,732
SNPs using high-density oligonucleotide, photolithographic microarrays at
Perlegen Sciences. For stage 2, genotyping was performed using 2.5mg genomic
DNA. These samples were genotyped for a set of 13,023 SNPs selected on the
basis of the stage 1 results, using a custom designed oligonucleotide array. For
both stages, each SNP was interrogated by 24 25-mer oligonucleotide probes
synthesized by photolithography on a glass substrate. The 24 features comprise 4
sets of 6 features interrogating the neighbourhoods of SNP reference and alterna-
tive alleles on forward and reference strands. Each allele and strand is represented
by five offsets:22,21, 0, 1 and 2 indicating the position of the SNP within the
25-mer, with zero being at the thirteenth base. At offset 0 a quartet was tiled,
which included the perfect match to reference and alternative SNP alleles, and
the two remaining nucleotides as mismatch probes. When possible, the mis-
match features were selected as a purine nucleotide substitution for a purine
perfect match nucleotide and a pyrimidine nucleotide substitution for a pyri-
midine perfect match nucleotide. Thus, each strand and allele tiling consisted of
6 features comprising five perfect match probes and one mismatch.
Individual genotypes were determined by clustering all SNP scans in the two-
dimensional space defined by reference and alternative trimmed mean intens-
ities, corrected for background. Allele frequencies were approximated using the
intensities collected from the high-density oligonucleotide arrays. An SNP’s
allele frequency, p, was estimated as the ratio of the relative amount of the
DNA with reference allele to the total amount of DNA. The p^ value was com-
puted from the trimmed mean intensities of perfect match features, after sub-
tracting a measure of background computed from trimmedmeans of intensities
of mismatch features. The trimmedmean disregarded the highest and the lowest
intensity from the five perfect match intensities before computing the arithmetic
mean. For themismatch features, the trimmedmean is the individual intensity of
the specified mismatch feature.
The genotype clustering procedure was an iterative algorithm developed as a
combination of K-means and constrained multiple linear regressions. The
K-means at each step re-evaluated the cluster membership representing distinct
diploid genotypes. The multiple linear regressions minimized the variance in p^
within each cluster while optimizing the regression lines’ common intersect. The
common intersect defined a measure of common background that was used to
adjust the allele frequencies for the next step of K-means. The K-means and
multiple linear regression steps were iterated until the cluster membership and
background estimates converged. The best number of clusters was selected by
maximizing the total likelihood over the possible cluster counts of 1, 2 and 3
(representing the combinations of the three possible diploid genotypes). The
total likelihoodwas composed of data likelihood andmodel likelihood. The data
likelihood was determined using a normal mixture model for the distribution of
p^ around the cluster means. The model likelihood was calculated using a prior
distribution of expected cluster positions, resulting in optimal p^ positions of 0.8
for the homozygous reference cluster, 0.5 for the heterozygous cluster and 0.2 for
the homozygous alternative cluster.
A genotyping quality metric was compiled for each genotype from 15 input
metrics that described the quality of the SNP and the genotype. The genotyping
quality metric correlated with a probability of having a discordant call between
the Perlegen platform and outside genotyping platforms (that is, non-Perlegen
HapMap project genotypes). A system of 10 bootstrap aggregated regression
trees was trained using an independent data set of concordance data between
Perlegen genotypes and HapMap project genotypes. The trained predictor was
then used to predict the genotyping quality for each of the genotypes in this data
set. Genotypes with quality scores of less than 7 were discarded. Data were
analysed for 227,876 SNPs in stage 1 and 12,026 (of 13,023 selected) in stage
2, for which the call rate was .80%.
The 12,711 SNPs for stage 2 were primarily selected on the basis of a 1 d.f.
Cochran-Armitage trend test (11,809, all with P, 0.052). We also included 826
SNPs with P, 0.01 testing for the difference in frequency of either homozygote
between cases and controls (that is, assuming either a dominant or recessive
model) and 76 SNPs that achieved P, 0.01 on a Cochran-Armitage test, weight-
ing individuals by their family history score as above.
For the main analyses, we discarded SNPs with a call rate,90% in stage 1 and
95% in stage 2, and SNPs with a deviation from Hardy–Weinberg equilibrium
significant at P, 0.00001 in either stage, leaving 205,586 SNPs in stage 1 and
10,621 SNPs in stage 2.
The 30 SNPs included in the stage 3 analyses were initially selected on the basis
of a combined analysis of stage 1 and stage 2. We included all SNPs achieving a
combined P, 0.00002 (based on either the Cochran-Armitage or 2 d.f. test, see
below). Following re-evaluation of the stage 2 genotyping by 59 nuclease assay
(Taqman, Applied Biosystems) using the ABI PRISM 7900HT (Applied
Biosystems), and exclusion of some samples, 16 of these SNPs were significant
at P, 0.00002 and 24 at P, 0.0002 (Supplementary Table 3). One additional
SNP, rs3803662, was added as a result of fine-scale mapping of the TNRC9/
LOC643714 locus.
The 31 stage 3 SNPs were genotyped in 22 studies (including cases and con-
trols from SEARCHnot used in stage 2, together with 21 other studies). For 18 of
the studies, genotyping was performed by 59 nuclease assay (Taqman) using the
ABI PRISM 7900HT or 7500 Sequence Detection Systems according to manu-
facturer’s instructions. Primers and probes were supplied directly by Applied
Biosystems (http://www.appliedbiosystems.com/) as Assays-by-Design. All
assays were carried out in 384-well or 96-well format, with each plate including
negative controls (with noDNA). Duplicate genotypes were provided for at least
2% of samples in each study. For three studies, SNPs were genotyped using
matrix assisted laser desorption/ionization time of flight mass spectrometry
(MALDI-TOF MS) for the determination of allele-specific primer extension
products using Sequenom’s MassARRAY system and iPLEX technology. The
design of oligonucleotides was carried out according to the guidelines of
Sequenom and performed using MassARRAY Assay Design software (version
1.0). Multiplex PCR amplification of amplicons containing SNPs of interest was
performed using Qiagen HotStart Taq Polymerase on a Perkin Elmer GeneAmp
2400 thermal cycler (MJ Research) with 5 ng genomic DNA. Primer extension
reactions were carried out according to manufacturer’s instructions for iPLEX
chemistry. Assay data were analysed using Sequenom TYPER software (version
3.0). One study used both the Taqman and MALDI-TOF MS approaches. The
SNPs genotyped in stage 3 were also regenotyped in the stage 2 samples using
Taqman; these genotype calls were used in the overall analyses (Table 2,
Supplementary Table 3, and Fig. 2).
We eliminated any sample that could not be scored on 20% of the SNPs
attempted. We also removed data for any centre/SNP combination for which
the call rate was less than 90%. In any instances where the call rate was 90–95%,
the clustering of genotype calls was re-evaluated by an independent observer to
determine whether the clustering was sufficiently clear for inclusion. We also
eliminated all the data for a given SNP/centre where the reproducibility in
duplicate samples was ,97%, or where there was marked deviation from
Hardy–Weinberg equilibrium in the controls (P, 0.00001).
Fine-scale mapping of FGFR2. Initial tagging of the associated region was done
by identifying all SNPs with an m.a.f.. 5% in the HapMap CEPH/CEU set
(Utah residents with ancestry from northern and western Europe). We then
selected 7 SNPs (in addition to rs2981582) that tagged these variants with a
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pairwise r2. 0.8, using the program Tagger (http://www.broad.mit.edu/mpg/
tagger/)37. To identify additional common variants within the 32.5 kb region of
linkage around the associated SNP,we resequenced 45 lymphocyteDNA samples
from a subset of European subjects also genotyped by HapMap and other pub-
licly available data sets. Seventy overlapping PCR amplicons were designed from
positions 123317613 to 123348192 of chromosome 10 (average amplicon size
650 bp, 160 bp overlap). M13-tagged PCR products were bidirectionally
sequenced using Big Dye 3.0 (Applied Biosystems) and processed using auto-
mated trace analysis through the Cancer Genome Workbench (cgwb.nci.nih.-
gov). Eighty-six per cent of the nucleotides across the region could be scored for
polymorphisms in at least 80% of subjects. This set gave a.97% probability of
detecting a variant with an m.a.f.. 5%. One hundred and seventeen variants
were identified, including 27 present in dbSNP but without individual genotype
information in European subjects, and an additional 46 not in dbSNP.
Individual genotype information was then compared and merged with publicly
available genotypes from Caucasian subjects (HapMap release 21 for 60 CEU
parents, 22 European subjects from the Environmental Genome Project (EGP)
resequencing effort (http://egp.gs.washington.edu/data/fgfr2/), and 24 Euro-
pean subjects from Perlegen (retrieved through http://gvs.gs.washington.edu/
GVS)). There were 2 discrepancies among 389 genotype calls among subjects
in common between our resequencing effort and EGP or Perlegen data, and 10
out of 926 compared to HapMap genotypes.
On the basis of these data, we identified 28 SNPs correlated with rs2981582
with r2. 0.6.We then attempted to genotype these 28 SNPs, plus rs2981582, in a
subset of 80 controls from SEARCH and 84 controls from the Seoul Breast
Cancer Study. Twenty-two of the variants were genotyped using Taqman.
Four further variants (rs34032268, rs2912778, rs2912781 and rs7895676), which
were not amenable to Taqman, were genotyped by Pyrosequencing (Biotage;
http://www.biotagebio.com/). Assays were designed using Pyrosequencing
Assay Design Software 1.0. The remaining 2 SNPs (rs35393331 and
rs33971856) could not be genotyped using either technology and were excluded
from further analyses.We cannot therefore comment on their likelihoodof being
the causal variant. Using these data, we selected tagging sets of 11 SNPs for UK
subjects and 14 SNPs for Korean subjects (including rs2981582), such that each
of the remaining variants was correlated with a tagging SNP with r2. 0.95 in the
UK study or r2. 0.86 in the Korean study. After genotyping the 11 tag SNPs in
SEARCH, two of these SNPs (rs4752569 and rs35012336) showed strong evid-
ence against being the causative variant and were not considered further. The
remaining 12 tag SNPs from the Korean subset were then genotyped in the
samples from the IARC-Thai Breast Cancer Study, the Breast Cancer Study in
Taiwan and the Multi-Ethnic Cohort (MEC), by Taqman.
Statistical methods. The primary test used for each SNP was a Cochran-
Armitage 1 d.f. score test for association between disease status and allele dose.
In the combined analysis, we performed a stratified Cochran-Armitage test.
Stage 1 was given a weight of 4 in this analysis (corresponding to a weight of 2
in the score statistic), to allow for the expected greater effect size given the
inclusion of cases with a family history. In the stage 3 analyses, each study was
treated as a separate stratum, except for the MEC, in which the European
American and Japanese American subgroups were treated as separate strata.
For all studies except the MEC, individuals from a minor ethnic group for that
study were excluded. Per-allele and genotype-specific odds ratios, and confid-
ence intervals, were estimated using logistic regression, adjusting for the same
strata. The summary odds ratios in Fig. 2 are based on the data from the stage 3
studies only, to avoid the bias inherent in estimates from the stage 1 and 2 data
for SNPs exhibiting an association (the so called ‘winner’s curse’). The effects of
genotype on family history of breast cancer (first degree yes/no) and bilaterality
were examined by treating these variables as outcomes in a stratified Cochran-
Armitage test.
To assess the global significance of the SNPs in stage 3, we computed the sum
of the x2 trend statistics (excluding the 6 SNPs reaching genome-wide signifi-
cance, plus rs2107425 as it was in LDwith rs3817198) over those SNPs (17 of 23)
for which the estimated odds ratios in stage 3 were in the same direction as the
combined stage 1/stage 238. Under the null hypothesis of no association, the
asymptotic distribution of this statistic is x2 with n degrees of freedom, where
n has a binomial distributionwith parameters 23 and 1/2. The significance of this
statistic was then assessed by computing a weighted sum of the tails of the
relevant x2 distributions.
For the fine-scale mapping of the FGFR2 locus, we first derived haplotype
frequencies using the haplo.stats package in S-plus39, separately for the European
andAsian populations, using data from the case-control studies onwhom the tag
SNPs were typed plus the 164 control individuals on whom all SNPs were typed.
These were used to impute genotype probabilities for each identified SNP in each
individual. We then used an EM algorithm to fit a logistic regression model
assuming that each SNP in turn was the causal variant, allowing for uncertainty
in the genotypes of untyped SNPs, and hence to determine the likelihood that
each SNP was the causal variant.
Coverage of the stage 1 tagging set was estimated using HapMap phase II as a
reference. We based estimates on 2,116,183 SNPs with an m.a.f. of .5% in the
CEU population. Of the SNPs successfully genotyped in stage 1, 187,663 were
also onHapMap. For those SNPs not onHapMap, we identified ‘surrogate’ SNPs
that were in perfect LD based on genotyping of 24 Caucasians by Perlegen
Sciences (269,203 SNPs)18. To estimate coverage, we determined the best pair-
wise r2 for each HapMap SNP and each tag SNP or a surrogate SNP, using the
HapMap CEU data. This coverage was summarized in terms of the distribution
of r2 by allele frequency in 10 categories.
To estimate the power to detect each of the associations found, we computed
the non-centrality parameter for the test statistic at each stage, based on the per-
allele relative risk, allele frequency and r2. This was used to estimate the power for
a given r2, based on a simulated trivariate normal distribution for the score
statistics after each stage to allow for the correlations in the test statistics. We
assumed a cut-off of P, 0.05 for stage 1, P, 0.00002 for stage 2 and P, 1027
for stage 3 (the first is slightly conservative, as more SNPs than this were actually
taken forward). The overall power was obtained by averaging the power esti-
mates for each r2 over the distribution of r2 obtained from the HapMap data,
applicable to a SNP of that frequency.
The expected number of significant associations after stage 2 (Table 1) was
calculated using a bivariate normal distribution for the joint distribution of the
(weighted) Cochran-Armitage score statistics after stage 1 and after both stages,
using a correlation of 0.525 between the two statistics (reflecting the weighted
sizes of the two studies). These calculations were based on the 205,586 SNPs
reaching the required quality control in stage 1. Of these, 11,313 reached a
P, 0.05, of which 7,405 (65.5%) were successfully genotyped to the required
quality control in stage 2. Thus the expected number reaching a given signifi-
cance level with good quality control was calculated from the total number
expected to reach this level 3 65.5%. We adjusted the variances of the test
statistics, separately for stages 1 and 2, using the genomic control method22.
The adjustment factor, l, was estimated from the median of the smallest 90%
of the test statistics for SNPs typed in that stage, divided by the predictedmedian
for the smallest 90% of a sample of x21 distributions (that is, the 45% percentile
of a x21 distribution, 0.375).
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